Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine > News > Cancer metastasis hijacks process healthy cells use to move around the body
  • News

Cancer metastasis hijacks process healthy cells use to move around the body

  • 7 October 2022
  • Janet Fricker
Cancer metastasis hijacks process healthy cells use to move around the body
Total
0
Shares
0
0
0
0
0

Blocking the activity of an ion channel in a mouse model of cancer triggered metastasis independent of tumour formation. The study, published in Nature Genetics, 29th September, found that the process was not just restricted to mice with cancer; when NALCN was removed from mice without cancer it caused healthy cells to leave their original tissue and travel around the body.

“Not only have we identified one of the elusive drivers of metastasis, but we have also turned a commonly held understanding of this on its head, showing how cancer hijacks processes in healthy cells for its own gains. If validated through further research, this could have far-reaching implications for how we prevent cancer from spreading and allow us to manipulate this process to repair damaged organs,” says Richard Gilbertson, Group Leader for the study and Director of the Cancer Research UK Cambridge Centre.

The most common cause of cancer death is metastasis, the process by which cancer cells spread from the primary tumour to other organs, which ultimately leads to their loss of function. Blocking the process of metastasis could markedly improve the survival of patients with cancer, but how the process is triggered within the complex cascade of tumorigenesis has been unclear. “Because metastasis involves so many different processes, it has been hard to uncouple the processes involved in cells actually leaving the primary tumour from characteristics of the primary tumour itself,” says Eric Rahrmann, the lead researcher.

In the paper the investigators identify a single ion channel, sodium leak channel non-selective protein (NALCN), as a key regulator of epithelial cell trafficking to distant tissues. NALCN is known to be responsible for the background sodium leak conductance maintaining the resting membrane potential. It is known to regulate key functions in excitable tissues, for example respiration and circadian rhythms, and gain-of-function mutations have been associated with neurological disorders.

However, little is known about the role of NALCN in non-excitable tissues. The team first focussed on NALCN following experiments comparing gene expression profiles of normal and malignant gastric stem cells to identify the earliest changes in tumour initiation. They identified a selective silencing of ion channels and solute carriers in the malignant stem population. One of these genes, Nalcn, encodes the ion channel responsible for the resting membrane potential of cells, and was the only gene significantly mutated in human gastric cancer. Among 10,022 human cancers within The Cancer Genome Atlas, they found that NALCN loss of function mutations were shown to be enriched in gastric, colorectal, lung, prostate and head and neck cancer.

First, the team showed that deletion of NALCN from gastric, intestinal or pancreatic adenocarcinomas in mice did not alter tumour incidence, but increased the number of circulating tumour cells (CTCs) and metastases.

Next, they took their control mice (where NALCN had not been deleted) and treated them with gadolinium – a NALCN channel blocker – and showed that animals treated with gadolinium had significant increases in CTCs and metastasis. “Not only could we do this genetically but also pharmacologically recapitulated these findings as well,” says Rahrmann.

Finally, deletion of NALCN from mice that lacked oncogenic mutations, and never developed cancer, caused shedding of epithelial cells into the blood at levels equivalent to those seen in tumour-bearing animals. These cells trafficked to distant organs to form normal structures including lung epithelium and kidney glomeruli and tubules.

“We have uncoupled the process of metastasis from cancer. Metastasis in itself appears to be a normal process, with NALCN regulating this process and also mobilising endogenous epithelial stem cell pools for tissue regeneration,” says Rahrmann.

In the future, manipulation of NALCN could function as a promising new approach to block metastasis. For example, drugs capable of reopening the NALCN channel might offer effective antimetastatic therapies. “When a person is diagnosed with a primary tumour you could prescribe a treatment that reduces metastasis right away to prevent the shedding of tumour cells during surgery,” suggests Rahrmann.

The group now plan further studies, including looking more ‘mechanistically’ to explore what regulates the expression of NALCN, looking at the metastatic potential of specific NALCN mutations, and extrapolating the work to other types of cancer. “Since NALCN is not the only ion channel that regulates resting potential, we are looking more globally to see whether other types of channels could also be implicated in a similar process,” says Rahrmann. “We are also looking at tissue generation to see if we can harness already existing stem cell pools within our body to leverage them to repair damaged tissue.”

One concern raised by the study that needs to be addressed, he adds, is that limited exposure to gadolinium-contrast imaging has been linked to gadolinium-induced systemic fibrosis, which in cancer patients could accelerate metastasis.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • gadolinium
  • metastasis
  • resting membrane potential
  • sodium leak channel non-selective protein
  • tissue regeneration
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • Articles
  • Delivery of Care

Tackling cancer when there’s no functioning state: the Al-Amal model

  • 7 October 2022
  • Marwa Koçak
View Post
Next Article
  • Articles
  • Biology basic

Cancer and the immune system: turning insights into treatments

  • 7 October 2022
  • Anna Wagstaff
View Post
You May Also Like
View Post
  • News

Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study

  • Yeva Margaryan
  • 8 May 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in April: Oncology’s Top Moments

  • Yeva Margaryan
  • 7 May 2025
View Post
  • News

CancerWorld #102 (April 2025)

  • Yeva Margaryan
  • 22 April 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in March: Oncology’s Top Moments

  • Yeva Margaryan
  • 8 April 2025
View Post
  • News

Ovarian cancer: mechanism conferring resistance to immunotherapy revealed

  • Janet Fricker
  • 21 March 2025
View Post
  • News

Muscular strength and cardiorespiratory fitness improve survival in cancer patients

  • Janet Fricker
  • 20 March 2025
View Post
  • News

CancerWorld #101 (February 2025): The Must-Read Oncology Issue Returns to Print with Exclusive Interviews and Breakthroughs

  • Yeva Margaryan
  • 18 March 2025
View Post
  • News

Low-dose aspirin reduces colorectal cancer recurrence in patients with PI3K alterations

  • Janet Fricker
  • 6 March 2025
search
CancerWorld #101 Download CancerWorld #101 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study
    • 8 May 2025
  • What Caught Our Eye in April: Oncology’s Top Moments
    • 7 May 2025
  • CancerWorld #102 (April 2025)
    • 22 April 2025
  • What Caught Our Eye in March: Oncology’s Top Moments
    • 8 April 2025
  • Ovarian cancer: mechanism conferring resistance to immunotherapy revealed
    • 21 March 2025
Article
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • Istanbul, Ankara take action on HPV vaccination, as government delays promised national programme
    • 1 April 2025
  • Could this dual approach be the frontier that finally gets immunotherapy to work for MSS colorectal cancer?
    • 31 March 2025
Social

Would you follow us ?

Contents
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • “I really care about people.” – Philip Kantoff, A Life in Science and Medicine
    • 5 May 2025
  • What If the World’s Leading Prostate Cancer Epidemiologist Opened a Restaurant? A Conversation with Lorelei Mucci- A Harvard Scientist, A Mother, A Leader
    • 23 April 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.